Cullinan Therapeutics, Inc. Common Stock
Symbol: CGEM (NASDAQ)
0.00
▼ (-100.00%) -5.930
Company Description:
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $5.93
- Yesterday High: $6.055
- Yesterday Low: $5.89
- Yesterday Volume: 1.07M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Cullinan Therapeutics, Inc. Common Stock
- Website: https://cullinantherapeutics.com
- Listed Date: 2021-01-08
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001789972
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $350.31M
- Round Lot: 100
- Outstanding Shares: 59.07M
- Asset Type: CS
RECENT FILINGS FOR CGEM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-04 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 3 | View |
| 2025-08-08 | 3 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-04 | 8-K | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
Latest News on CGEM